PARP1 and melanoma: As a proof, PARP-1 inhibition in melanoma and cervical carcinoma lines enhanced in vitro sensitivity to temozolomide (Tentori et al., 2010) and promotes antitumor activity in ETS gene-rearranged PCa models (de Bono et al., 2011).